DGAP-News: Eckert & Ziegler fiscal year 2013: slight

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 27, 2014 at 3:00 AM

DGAP-News: Eckert & Ziegler fiscal year 2013: slight decrease in sales. Proposed dividend unchanged. Optimistic for fiscal year 2014.

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Final Results/Dividend Eckert & Ziegler fiscal year 2013: slight decrease in sales. Proposed dividend unchanged. Optimistic for fiscal year 2014. 27.03.2014 / 07:45 --------------------------------------------------------------------- Berlin, March 27, 2014. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, reported sales of EUR 117.1 million in 2013 (previous year: EUR 120.0 million). The decisive factors for this development were the decline in sales in industrial components, implants and instruments, the planned exit from the accessories trade in France as well as the unfavorable EUR/USD exchange rate. Additional sales from acquisitions were unable to compensate for these effects. Consolidated net profit after taxes and minority interests fell by 12% from EUR 10.3 million to EUR 9.1 million, and earnings per share dropped EUR 0.23/share to EUR 1.72. The main reason for this was the decline in the gross margin, which was down 12% due to one-off effects although sales only registered a 2% decline. Higher sales costs as a result of higher one time waste costs as well as a shift in the product mix to low-margin products were also responsible. A sales breakdown by segment shows the following sales distribution: The Radiation Therapy segment reported the largest nominal decline in sales of EUR 3.9 million to EUR 27.8 million. Special sales in the previous year from a one-off license fee for the use of Company patents and technologies in Russia and the discontinuation of the radiation accessories business in France were the two factors responsible for this. Adjusted for these effects, sales in the Radiation Therapy segment grew in particular on the back of stable demand for tumor irradiation equipment (+7%). Sales in the Isotope Products segment contracted 4% to EUR 54 million due to the lower demand for industrial components in China and America as well as unfavorable exchange rate effects. Sales in the Radiopharma segment increased by EUR 2.3 million or 9%. This was largely a result of the acquisition of Austrian company BSM Diagnostica GmbH, which contributed EUR 3.0 million to sales. A foreign acquisition also significantly contributed to sales growth in the Environmental Services segment at EUR 1.6 million. Sales increased EUR 1.1 million or 18% on the back of the first-time inclusion of the British waste management business acquired from Energy Solutions. Overall, sales and earnings are expected to see at least 10% growth in fiscal year 2014. This corresponds to sales of some EUR 129 million and net profit of around EUR 10 million (EPS approx. EUR 1.90/share) for the year. Internal planning figures are considerably higher than these threshold values. The complete annual financial statements can be viewed under: http://www.ezag.com/home/investors/financial-reports.html The Executive Board and Supervisory Board will propose to the Annual General Meeting on May 22, 2014, a dividend of EUR 0.60 per share entitled to a dividend (previous year: EUR 0.60). About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 700 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine. Contributing to saving lives. For further information or questions, please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-RÃ¶ssle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de End of Corporate News --------------------------------------------------------------------- 27.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-RÃ¶ssle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, MÃ¼nchen End of News DGAP News-Service --------------------------------------------------------------------- 259824 27.03.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FOX News Sweeps 2026 Midterms Coverage Ratings

FOX News Outshines Rivals in Midterm Coverage Diving into the chaos of the 2026 midterm elections, it’s clear FOX News Media’s strategic playbook outmaneuvered its cable competitors, chalking up a dominant ratings victory. Nielsen's final count places FOX News Channel (FNC) in the spotlight, their primetime broadcast drawing nearly 4.7 million viewers. And while some...

Clean Energy: How COP31 Can Change the Future

Global Warming: A Battle Heating Up Fast It's like trying to run uphill while carrying the baggage of outdated promises. We’ve got business bigwigs rallying at COP31, demanding the world to get serious about clean energy. If they don’t, we're looking at warming rocketing up to 2.6°C come year 2100. Who's listening though? The Call for Clean Electrification This mob,...

FX's Game-Changer: Stemless Reverse Shoulder System

Stirring Up the Shoulder Market You gotta hand it to FX Shoulder Solutions – they've managed to elbow their way into the medical device market with something truly revolutionary. With the FDA clearance of Easytech Reversed®, a stemless reverse shoulder arthroplasty system, they're not just playing the innovation game; they're setting a whole new rulebook. This isn't...

Seniors and Cybersecurity: Tackling Holiday Threats

Battle Against the Holiday Cyber Threats This ain't just about slipping on an ugly sweater this holiday season. The ugly truth is as the colder weather rolls around, so do the cyber vultures—praying on the unsuspecting, especially our seniors. Fraudsters are cranking up the heat, exploiting online shopping sprees, hefty travel plans, and even the warm embrace of a...

Beetles Gel Polish Debuts Bold Halloween Nail Kit

Diving Deep into Beetles Gel Polish's Gothic Launch In a world where nail polish can ignite passions and trends, Beetles Gel Polish is pulling out all the stops with its latest Halloween venture. This ain't your average nail kit, folks. We're talking about the Vampiric Feast Gift Box—an 8-color powerhouse designed to transform your nails into bloody, gothic...

XCMG Spurs 'AI + Construction' Innovation at Event

XCMG's Big Push for Smarter Machinery China's construction machinery titan XCMG just wrapped up a fireworks show of innovation in Xuzhou, highlighting some sharp AI-driven machinery projects. Their recent 'AI + Construction Machinery' competition pulled in minds from over 20 countries, all aiming to rethink how these hulking machines operate. AI and Machinery: A Match...

Hyperliquid Strategies Navigates High Stakes in Fintech

Hyperliquid's Bold Moves in a Volatile Market Hyperliquid Strategies Inc (NASDAQ: PURR) isn't just sitting on the sidelines, folks. They're not dipping their toes, they're cannonballing into the deep end, reporting impressive financial strides as Q3 2026 wraps up. Deploying a whopping $802 million and filing to become a futures commission merchant? That's like setting the...

Coinhub Funded's Bold Move in Trading World

A New Name in the Trading Game Right out of Charlestown, Saint Kitts and Nevis, Coinhub Funded is making waves in the crypto prop trading world, and boy, they're not pulling any punches. They've just thrown their hat in the ring with a tantalizing offer: get your hands on a funded trading account up to $200K, and if that's not enough to get your pulse racing, they've got...

MetaVia's DA-1726 Impresses with Liver Fat Reduction

A Statistical Leap in Liver Fat Reduction MetaVia's latest Phase 1 data for DA-1726 makes a splash with a 68% reduction in liver fat, and I can't say I'm not intrigued. When results like these hit the table, it gives those of us who keep a close watch on the biotechnology world reason to pause. The reduction in liver fat isn't just another number; it's a chart-buster...

Workday: Dominating Cloud ERP with AI Prowess in 2026

Workday: A Force in the Cloud ERP Arena Right on! Workday's making waves again in the world of Cloud ERP. In a move that seems to defy the competition, they've locked down their spot as a Leader in the 2026 Gartner Magic Quadrant for Cloud ERP for Service-Centric Enterprises for the fifth year running. Consistency isn’t a coincidence here, folks—this is pure strategy!...